Novel Targeted Therapy, Immunotherapy, and Immune Biomarkers for Gastroesophageal and Liver Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1268
Special Issue Editors
Interests: gastric cancer; esophageal cancer; colon cancer; hepatocellular carcinoma; bile duct cancer
Special Issues, Collections and Topics in MDPI journals
Interests: developmental therapeutics; molecularly targeted agents; epigenetic modifiers; small molecule inhibitors; immune-oncology; bispecifics; T-cell engagers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Targeted therapy for cancer involves inhibiting tumor growth by disrupting essential chemical pathways or mutant proteins. Conversely, immunotherapy aims to provoke a host immune response, culminating in tumor destruction. These strategies manifest heightened efficacy within specific subsets of gastroesophageal cancer patients.
Gastroesophageal cancer, encompassing gastric and esophageal carcinomas along with gastroesophageal junction carcinoma, is a prevalent malignancy in the gastrointestinal realm. It ranks fourth and fifth globally in terms of incidence and mortality, respectively. Hepatocellular carcinoma (HCC) is one of the most common and lethal hepatic malignancies. The development of personalized regimens, including vaccine therapies and adoptive cell treatments, coupled with an intricate comprehension of immune response predictive biomarkers, holds promise for optimizing therapeutic outcomes.
This Special Issue is dedicated to shedding light on therapeutic advances for gastroesophageal cancer and HCC. It will encompass insights into novel standard and investigational treatment interventions involving targeted therapy and immunotherapy in this population. The emphasis is on research work highlighting or investigating potential prognostic and therapeutic predictive biomarkers of those novel therapeutics.
You may choose our Joint Special Issue in Current Oncology.
Dr. Anwaar Saeed
Dr. Ludimila Cavalcante
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- targeted therapy
- immune checkpoint inhibitors
- gastroesophageal cancer
- liver cancer
- biomarkers
